行情

SNSS

SNSS

Sunesis Pharma
NASDAQ

实时行情|Nasdaq Last Sale

0.3720
-0.0190
-4.86%
盘后: 0.4000 +0.028 +7.53% 18:55 11/15 EST
开盘
0.3990
昨收
0.3910
最高
0.4000
最低
0.3600
成交量
75.12万
成交额
--
52周最高
1.770
52周最低
0.2000
市值
4,141.10万
市盈率(TTM)
-0.7075
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SNSS 新闻

  • Edited Transcript of SNSS earnings conference call or presentation 12-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.3小时前
  • Sunesis Pharmaceuticals, Inc. (SNSS) Management on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.2天前
  • Sunesis Pharmaceuticals EPS beats by $0.03
  • seekingalpha.2天前
  • Sunesis Pharmaceuticals Q3 EPS $(0.06) Beats $(0.08) Estimate
  • Benzinga.3天前

更多

所属板块

生物技术和医学研究
+1.49%
制药与医学研究
+1.29%

热门股票

名称
价格
涨跌幅

SNSS 简况

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company’s lead programs are Vecabrutinib, SNS-510 and TAK-580. The Company also offers Vosaroxin, an anticancer quinolone derivative (AQD), which is used for the treatment of acute myeloid leukemia (AML). Vecabrutinib is a selective, reversible, non-covalent binding inhibitor of Bruton's tyrosine kinase (BTK) inhibitors. SNS-510 is a phosphoinositide dependent protein kinase 1 (PDK1) inhibitors. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors.
展开

Webull提供Sunesis Pharmaceuticals, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。